Al-Sofiani Mohammed E, Almehthel Mohamed, Al Ozairi Ebaa, Sadik Jamaa, Hao Lichen, Akil Yasser
Endocrinology Unit, Internal Medicine Department, College of Medicine, King Saud University, 11461, Riyadh, Saudi Arabia.
Division of Endocrinology, Diabetes, & Metabolism, Johns Hopkins University, Baltimore, MD, USA.
Diabetes Ther. 2025 Jul 21. doi: 10.1007/s13300-025-01772-1.
My Dose Coach (MDC) is a digital smartphone application approved in multiple countries, including Saudi Arabia and Kuwait, to help people with type 2 diabetes (T2D) titrate their basal insulin as per their clinician-guided, individualized diabetes care plan.
A retrospective, observational cohort analysis was conducted on MDC user data collected from 1 January 2021 to 1 June 2023 in Saudi Arabia and Kuwait. Primary outcome was change in fasting blood glucose (FBG). Key secondary outcomes included time to achieve FBG and HbA targets, and time to first hypoglycemia event. Outcomes were analyzed by FBG target status and frequency of MDC usage (high: > 3 days per week; moderate: > 1- ≤ 3 days per week; low: ≤ 1 day per week).
Among all users (N = 494), mean ± SD FBG decrease was -44.4 ± 72.5 mg/dL. Mean ± SD time to achieve FBG target was 14.8 ± 20.9 days and 12.8 ± 18.8, 29.1 ± 28.0, and 43.5 ± 41.7 days for high-, moderate-, and low-frequency MDC users, respectively. Individualized FBG targets were achieved by 276 (55.9%) users, and high-frequency of MDC use was associated with better target achievement (p < 0.01). Mean ± SD time to achieve HbA target was 48.0 ± 40.5 days. Reduction in HbA was more in high-frequency MDC users (18.3%) than low-frequency MDC users (6.3%). Mean ± SD time to the first hypoglycemia event was 4.86 ± 4.8 days. Hypoglycemia events were reported in only seven (1.4%) participants and not significantly correlated with MDC use frequency (p = 0.1431).
Current findings show that using MDC is associated with improved glycemic control in people with T2D in Saudi Arabia and Kuwait, with greater benefits observed with higher frequency MDC usage.
“我的剂量教练”（MDC）是一款在包括沙特阿拉伯和科威特在内的多个国家获得批准的数字智能手机应用程序，旨在帮助2型糖尿病（T2D）患者根据临床医生指导的个性化糖尿病护理计划调整基础胰岛素剂量。
对2021年1月1日至2023年6月1日在沙特阿拉伯和科威特收集的MDC用户数据进行回顾性观察队列分析。主要结局是空腹血糖（FBG）的变化。关键次要结局包括达到FBG和糖化血红蛋白（HbA）目标的时间，以及首次发生低血糖事件的时间。根据FBG目标状态和MDC使用频率（高：每周>3天；中：每周>1至≤3天；低：每周≤1天）对结局进行分析。
在所有用户（N = 494）中，FBG平均下降幅度为-44.4±72.5mg/dL。高、中、低频MDC用户达到FBG目标的平均时间分别为14.8±20.9天、12.8±18.8天、29.1±28.0天和43.5±41.7天。276名（55.9%）用户实现了个性化FBG目标，且MDC高使用频率与更好的目标达成相关（p<0.01）。达到HbA目标的平均时间为48.0±40.5天。高频MDC用户的HbA降低幅度（18.3%）高于低频MDC用户（6.3%）。首次发生低血糖事件的平均时间为4.86±4.8天。仅7名（1.4%）参与者报告了低血糖事件，且与MDC使用频率无显著相关性（p = 0.1431）。
目前的研究结果表明，在沙特阿拉伯和科威特，使用MDC与T2D患者血糖控制改善相关，MDC使用频率越高，益处越大。
